Cannabinoid and Modulator Composition for Ophthalmic Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ophthalmic conditions like blepharitis are inadequate due to compliance difficulties and side effects associated with steroids and antibiotics, which do not effectively address inflammation and pain.
Innovation Solution
A method involving the administration of a cannabinoid in combination with a modulator compound that acts as an NMDA receptor, 5-HT3 receptor, nicotinic acetylcholine receptor, dopamine D2 receptor, or sigma-1 receptor modulator, such as cannabidiol and memantine, to treat ophthalmic conditions, including blepharitis, by reducing inflammation and pain without the side effects of steroids and antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical steroids are used to treat the inflammatory aspects of blepharitis, then inflammation is reduced, but side effects occur
Solution Approach 1:
The patent introduces cannabinoids as intermediary compounds that mediate the anti-inflammatory effect through the endocannabinoid system. Instead of using steroids that directly suppress inflammation with harmful side effects, cannabinoids act as natural mediators that modulate the immune response through CB1 and CB2 receptors, achieving anti-inflammatory effects without the toxic side effects of traditional steroids.
Solution Approach 2:
The patent changes the chemical and pharmacological parameters of the treatment by switching from steroid molecules to cannabinoid molecules with different structural and functional properties. This parameter change includes using lipophilic compounds that can cross cell membranes and interact with cannabinoid receptors, fundamentally altering how anti-inflammatory action is achieved while avoiding steroid-related side effects.
2Reliability
If systemic tetracycline antibiotics are used to treat blepharitis, then bacterial overgrowth is controlled, but compliance difficulties and long-term use issues arise
Solution Approach 1:
The patent introduces topically administered cannabinoids as intermediaries that indirectly control bacterial overgrowth by addressing the underlying inflammation. Instead of using antibiotics that directly kill bacteria requiring long-term systemic administration, cannabinoids mediate the treatment by reducing inflammation, which in turn reduces bacterial proliferation, eliminating the need for prolonged antibiotic therapy and improving compliance.
3Reliability
If antibiotic ointments are used to treat bacterial overgrowth in blepharitis, then bacteria are reduced, but inflammatory aspects are not addressed
Solution Approach 1:
The patent makes the cannabinoid treatment universal by demonstrating its ability to simultaneously perform multiple functions: anti-inflammatory, antibacterial, and analgesic effects. The same topically applied cannabinoid composition addresses both bacterial overgrowth and inflammation through different mechanisms (direct antibacterial activity and CB receptor modulation), eliminating the need for separate treatments and providing versatile therapy for complex blepharitis cases.
4Reliability
If current therapies for blepharitis are used, then some symptoms are treated, but compliance difficulties and disappointing results occur
Solution Approach 1:
The patent merges multiple therapeutic functions into a single topical cannabinoid composition that simultaneously addresses inflammation, bacterial overgrowth, and pain. This combination approach consolidates what would otherwise require multiple separate treatments (steroids for inflammation, antibiotics for bacteria, analgesics for pain) into one unified therapy, simplifying the treatment regimen and improving patient compliance while achieving comprehensive symptom relief.
Data Source
AI summary
A method for treating ophthalmic conditions comprising the step of administering to a subject i) a cannabinoid, and ii) a modulator compound that acts as one or more of an NMDA receptor modulator, a 5-HT3 receptor modulator, a nicotinic acetylcholine receptor modulator, a dopamine D2 receptor modulator, or a sigma-1 receptor modulator; and compositions thereof.